Leslie Gilbert
Pediatric Hematology-Oncology · Greenville, SCNPI 1982838967
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Pierre Fabre Pharmaceuticals, Inc. at 45.4% of the total. Reporting peaked in 2023 at $4,136 and has fallen 83.2% since, to $696 in 2025.
Across 114 payments — averaging $72.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pierre Fabre Pharmaceuticals, Inc.$4K
- Abbott$2K
- Novo Nordisk$719
- CSL Behring$656
- Sanofi$355
- Novartis$240
- plus $781 from 18 others
Across 371 payments — averaging $43.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$16K
What the payments were for
- Travel & lodging$4,39853%
- Food & beverage$3,81446%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pierre Fabre Pharmaceuticals, Inc. | 8 | $3,743 |
| Abbott | 20 | $1,755 |
| Novo Nordisk | 14 | $719 |
| CSL Behring | 13 | $656 |
| Sanofi | 11 | $355 |
| Novartis | 8 | $240 |
| Pfizer | 8 | $141 |
| Bayer | 5 | $100 |
| Genentech, Inc. | 6 | $87 |
| Genentech USA, Inc. | 4 | $86 |
| Biomarin Pharmaceutical Inc. | 2 | $85 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Adaptive Biotechnologies Corporation | 1 | $34 |
| Day One Biopharmaceuticals | 1 | $32 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| RARE Disease Therapeutics, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $17 |
| Y-mabs Therapeutics, Inc. | 1 | $17 |
| Silvergate Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $13 |
| Emmaus Medical, Inc. | 1 | $12 |
| Octapharma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMANGEOL$3,362
- CardioMEMS HF System$1,065
- HEMGENIX$348
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$186
- Esperoct$125
- REBINYN$122
- NovoSeven$122
- Idelvion$103
How this compares
$8,248 in reported general payments places this provider in the 75th percentile of 32 pediatric hematology-oncology providers in South Carolina.
See all pediatric hematology-oncology providers in South Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 11 | $19,030 |
| Deferasirox | 12 | $1,975 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Greenville
- Alan AndersonGreenville$320K
- Howland CrosswellGreenville$14K
- Brianna MurphyGreenville$4K
- Nichole BryantGreenville$4K
- Aniket SahaGreenville$1K
- Rebecca CookGreenville$1K
- Chandni DarganGreenville$924
- Stephen MartinGreenville$699
- William SchmidtGreenville$0
- Shayla BergmannBeaufort$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.